News|Articles|December 31, 2025

Our Top 5 Most Viewed Video Interviews in 2025

Listen
0:00 / 0:00

Key Takeaways

  • NIH funding cuts impact intramural research, shared infrastructure, and early-stage academic research, leading to staffing reductions and rescinded PhD acceptances.
  • Legal and political ramifications of NIH funding freeze include institutional instability and potential constitutional implications if court rulings are defied.
SHOW MORE

Funding uncertainty, legal and political pressures, trade policy shifts, site collaboration strategies, and leadership perspectives were central themes across Applied Clinical Trials’ most-watched video interviews.

1. The Impact of Funding Cuts on Medical Research

In this video interview, Craig Lipset, co-chair, Decentralized Trials & Research Alliance (DTRA), discusses the impact of recent NIH funding cuts and federal regulatory decisions on medical research. Lipset explains how reductions in indirect cost reimbursements affect intramural research, shared infrastructure, and early-stage, higher-risk academic research. He also highlights downstream consequences, including staffing reductions, rescinded PhD acceptances, and constraints on FDA and NIH resources, as well as uncertainty surrounding diversity-related initiatives.

Watch the interview here.

2. Legal and Political Implications of the NIH Funding Freeze

In this interview, Ron Lanton, partner, Lanton Law, examines the legal and political ramifications of the NIH funding freeze and ongoing court challenges. Lanton outlines how reductions in indirect cost reimbursements and pauses in grant reviews threaten institutional stability and delay critical research. He discusses potential outcomes if the administration defies court rulings, warning of constitutional implications, and explains how researchers may be forced to seek private funding, potentially disadvantaging studies in areas such as cancer and sickle cell disease.

Watch the interview here.

3. Rising API Tariffs Are Forcing Pharma to Shift R&D Resources

In this video interview, Ron Lanton discusses how tariffs on active pharmaceutical ingredients (APIs) could increase drug development costs and disrupt the clinical trial supply chain. He explains that higher sourcing expenses may lead companies to reallocate resources away from maintaining or accelerating R&D pipelines. Lanton also notes that increased costs, combined with FDA inspection cuts, could slow approvals, reduce site readiness, and decrease the number of government-sponsored trials.

Watch the interview here.

4. 2025 SCRS Global Site Solutions Summit: Best Practices for Building Strong Site Partnerships and Choosing the Right Technology

In an interview from the 2025 SCRS Global Site Solutions Summit, Jimmy Bechtel, chief site success officer, SCRS, emphasizes the importance of internal organizational readiness to support effective site collaboration. He discusses challenges related to cultural buy-in, communication across organizational levels, and technology being imposed on sites without aligning to workflows. Bechtel underscores the need for infrastructure and workflow-focused technology choices that reduce site burden and free up coordinators and patient-facing staff to focus on patient care and engagement.

Watch the interview here.

5. 2025 DIA Global Annual Meeting: The Role of Leadership in Shaping the Future of Clinical Research

In this interview at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of growth & business development, DIA, reflects on the role of leadership amid evolving regulatory and funding challenges. Pierce highlights the importance of creating neutral forums where regulators, patients, academics, and industry stakeholders can engage in open dialogue and debate. She explains how leadership-driven collaboration and the exchange of diverse perspectives are essential to advancing science and improving patient care.

Watch the interview here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.